SANDRA GOFINET PASOTO

(Fonte: Lattes)
Índice h a partir de 2011
23
Lattes
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Autor: PASOTO, S. G. × Indexador: WoS ×

Resultados de Busca

Agora exibindo 1 - 10 de 10
  • article 0 Citação(ões) na Scopus
    Neurosarcoidosis during the treatment of primary Sjogren's syndrome: is it a paradoxical effect of rituximab?
    (2022) CORDEIRO, R. A.; OLIVEIRA, J. L. De; FERRACIOLLI, S. F.; GUEDES, L. K. N.; PASOTO, S. G.
  • conferenceObject
    IMMUNOPATHOLOGICAL SCENARIOS DEFINING COEXISTENCE BETWEEN SJOGREN SYNDROME AND SARCOIDOSIS
    (2022) FLORES-CHAVEZ, A.; NG, F.; ALUNNO, A.; INANC, N.; ABACAR, K. Y.; FEIJOO-MASSO, C.; SEROR, R.; HERNANDEZ-MOLINA, G.; HOFAUER, B.; PASOTO, S. G.; ROBLES, A.; AKASBI, M.; BRITO-ZERON, P.; LOPEZ-DUPLA, M.; RETAMOZO, S.; BANDEIRA, M.; ROMAO, V. C.; DEVAUCHELLE-PENSEC, V.; CARUBBI, F.; MARIETTE, X.; RAMOS-CASALS, M.
  • conferenceObject
    SAFETY AND EFFICACY OF SARS-COV-2 VACCINATION IN 1237 PATIENTS WITH PRIMARY SJOGREN SYNDROME
    (2022) INANC, N.; KOSTOV, B.; PRIORI, R.; FLORES-CHAVEZ, A.; CARUBBI, F.; SZANTO, A.; VALIM, V.; BOOTSMA, H.; PRAPROTNIK, S.; TREVISANI, V. F. M.; HERNANDEZ-MOLINA, G.; HOFAUER, B.; PASOTO, S. G.; DUPLA, M. L.; BOCCI, Bartoloni E.; RISCHMUELLER, M.; DEVAUCHELLE-PENSEC, V; ABACAR, K. Y.; GIARDINA, F.; ALUNNO, A.; HORVATH, I. F.; WOLFF, L. De; CALDAS, L.; RETAMOZO, S.; RAMOS-CASALS, M.; BRITO-ZERON, P.
  • article 3 Citação(ões) na Scopus
    Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjogren syndrome
    (2022) INANC, N.; KOSTOV, B.; PRIORI, R.; FLORES-CHAVEZ, A.; CARUBBI, F.; SZANTO, A.; VALIM, V.; BOOTSMA, H.; PRAPROTNIK, S.; TREVISANI, V. Fernandes Moca; HERNANDEZ-MOLINA, G.; HOFAUER, B.; PASOTO, S. G.; LOPEZ-DUPLA, M.; BARTOLONI, E.; RISCHMUELLER, M.; DEVAUCHELLE-PENSEC, V.; ABACAR, K.; GIARDINA, F.; ALUNNO, A.; HORVATH, I. Fanny; WOLFF, L. de; CALDAS, L.; RETAMOZO, S.; RAMOS-CASALS, M.; BRITO-ZERON, P.
    Objective To investigate the safety and efficacy of SARS-Cov-2 vaccination in patients with primary Sjogren syndrome (pSS) due to scarcity of data in this population. Methods By the first week of May 2021, all Big Data SS Consortium centres patients who had received at least one dose of any SARS-CoV-2 vaccine were included in the study. The in-charge physician asked patients about local and systemic reactogenicity to collect SARS-CoV-2 vaccination data. Results The vaccination data of 1237 patients were received. A total of 835 patients (67%) reported any adverse events (AEs), including local (53%) and systemic (50%) AEs. Subjective symptoms (63%) were the most common local AEs, followed by objective signs at the injection site (16%), and general symptoms were the most commonly reported systemic AEs (46%), followed by musculoskeletal (25%), gastrointestinal (9%), cardiopulmonary (3%), and neurological (2%). In addition, 141 (11%) patients reported a significant worsening/ exacerbation of their pre-vaccination sicca symptoms and fifteen (1.2%) patients reported active involvement in the glandular (n=7), articular (n=7), cutaneous (n=6), pulmonary (n=2), and peripheral nervous system (n=1) domains due to post-vaccination SS flares. In terms of vaccination efficacy, breakthrough SARS-CoV-2 infection was confirmed after vaccination in three (0.24 %) patients, and positive anti- SARS-Cov-2 antibodies were detected in approximately 95% of vaccinated SS patients, according to data available. Conclusion Our data suggest that patients with pSS develop adequate humoral response and no severe AEs after SARS-CoV- 2 vaccination and therefore raise no concerns about the vaccine's efficacy or safety profile in this population.
  • conferenceObject
    INFLUENCE OF EPIDEMIOLOGY AND ETHNICITY ON SYSTEMIC EXPRESSION OF PRIMARY SJOGREN SYNDROME AT DIAGNOSIS: WORLDWIDE PATTERNS IN 14,836 PATIENTS (2022 SJOGREN BIG DATA PROJECT)
    (2022) RETAMOZO, S.; SZANTO, A.; LI, X.; RASMUSSEN, A.; NG, F.; DONG, X.; PRIORI, R.; OLSSON, P.; BALDINI, C.; SEROR, R.; BOOTSMA, H.; ARMAGAN, B.; GOTTENBERG, J.; KRUIZE, A.; HERNANDEZ-MOLINA, G.; PAPROVNIK, S.; DANDA, D.; OZKIZILTAS, B.; INANC, N.; QUARTUCCIO, L.; SEBASTIAN, A.; GERLI, R.; ROMAO, V. C.; RISCHMUELLER, M.; SUZUKI, Y.; KWOK, S.; KVARNSTROM, M.; SOLANS, R.; PASOTO, S. G.; GALISTEO, C.; SENE, D.; TREVISANI, V Moca; ISENBERG, D.; HOFAUER, B.; SHIMIZU, T.; NORDMARK, G.; VALIM, V.; JURCUT, C.; CARUBBI, F.; GARCIA, A. Gonzalez; DEVAUCHELLE-PENSEC, D.; DIAZ, S. Melchor; GHEITA, T. A.; BRITO-ZERON, P.; LOPEZ-DUPLA, M.; FONSECA-AIZPURU, E.; SANCHEZ-BERNA, I; MOREL, J.; GIACOMELLI, R.; ATZENI, F.; CONSANI, C.; VAZQUEZ, M.; AKASBI, M.; FLORES-CHAVEZ, A.; RAMOS-CASALS, M.
  • article 2 Citação(ões) na Scopus
    Primary dental care treatment in primary Sjogren's syndrome: a possible role in improving salivary flow rate
    (2022) MARTINS, V. A. O.; FLORIANO, T. F.; LEON, E. P.; VILLAMARIN, L. E. B.; DEVEZA, G. B. H.; AIKAWA, N. E.; SILVA, C. A. A.; KUPA, L. V. K.; PERES, M. P. S. M.; BRAZ-SILVA, P. H.; BONFA, E.; PASOTO, S. G.
    Objective Primary Sjogren's syndrome (pSS) is an inflammatory chronic disorder that mainly affects exocrine glands. Additionally, oral infections can aggravate the glandular dysfunction. However, data on primary dental care (PDC) treatment in pSS are scarce. This study aimed to appraise the impact of PDC on the Xerostomia Inventory (XI), unstimulated/stimulated salivary flow rates and salivary cytokine profile in pSS. Methods Fifty-two pSS patients and 52 sex- and age-matched control participants without systemic autoimmune diseases were included in a prospective study. At inclusion, all participants were assessed through a standardised protocol, measurement of salivary pro-inflammatory cytokines, and underwent PDC. Dental procedures included: oral hygiene guidance, restorative treatment of caries, surgical removal of residual roots and impacted or partially erupted teeth, cysts, supra and subgingival periodontal scaling and treatment of soft tissue disorders (removal of lesions and treatment of opportunistic infections). After 3 months, the clinical/laboratorial assessments were repeated. Results At inclusion, the Decayed, Missing and Filled Teeth (DMFT) index was higher in the pSS patients than in the control group (13.3 +/- 8.2 vs. 8.6 +/- 6.2, p=0.002), whereas periodontal parameters were comparable in both groups (p>0.05). After PDC, 26.9% of pSS patients showed a reduction of at least 6 points (clinical improvement) in XI, but mean XI remained unchanged (p=0.285). PDC resulted in an increase in mean unstimulated (p<0.001) and stimulated (p=0.001) salivary flow rates in pSS, with no change in salivary cytokine profile (p=0.05). Conclusion PDC promoted improvement in unstimulated and stimulated salivary flow rates in pSS. This novel finding reinforces the recommendation of this strategy for pSS patients. Clinicaltrials.gov (Identifier: NCT03711214).
  • conferenceObject
    KEY FEATURES AT DIAGNOSIS OF PRIMARY SJOGREN SYNDROME IN 15,652 PATIENTS: 2022 SJOGREN BIG DATA PROJECT
    (2022) FLORES-CHAVEZ, A.; HORVATH, F. I.; LI, X.; RASMUSSEN, A.; NG, F.; DONG, X.; PRIORI, R.; OLSSON, P.; BALDINI, C.; SEROR, R.; BOOTSMA, H.; ARMAGAN, B.; GOTTENBERG, J.; KRUIZE, A.; HERNANDEZ-MOLINA, G.; PAPROVNIK, S.; DANDA, D.; OZKIZILTAS, B.; INANC, N.; SEBASTIAN, A.; BOCCI, Bartoloni E.; QUARTUCCIO, L.; ROMAO, V. C.; RISCHMUELLER, M.; SUZUKI, Y.; KWOK, S.; KVARNSTROM, M.; SOLANS, R.; PASOTO, S. G.; GALISTEO, C.; SENE, D.; TREVISANI, V. Moca; ISENBERG, D.; HOFAUER, B.; SHIMIZU, T.; NORDMARK, G.; VALIM, V.; JURCUT, C.; CARUBBI, F.; GARCIA, A. Gonzalez; RETAMOZO, S.; DEVAUCHELLE-PENSEC, V.; DIAZ, S. Melchor; GHEITA, T. A.; BRITO-ZERON, P.; LOPEZ-DUPLA, M.; FONSECA-AIZPURU, E.; SANCHEZ-BERNA, I.; MOREL, J.; GIACOMELLI, R.; ATZENI, F.; CONSANI, S.; VAZQUEZ, M.; AKASBI, M.
  • article 2 Citação(ões) na Scopus
    Characterisation of the coexistence between sarcoidosis and Sjogren's syndrome. Analysis of 43 patients
    (2022) FLORES-CHAVEZ, A.; NG, W-F; ALUNNO, A.; INANC, N.; FEIJOO-MASSO, C.; SEROR, R.; HERNANDEZ-MOLINA, G.; DEVAUCHELLE-PENSEC, V.; HOFAUER, B.; PASOTO, S. G.; ROBLES, A.; AKASBI, M.; LOPEZ-DUPLA, M.; RETAMOZO, S.; BANDEIRA, M.; ROMAO, V. C.; CARUBBI, F.; LOAIZA-CABELLO, D.; GARCIA-MORILLO, J. -S.; BENEGAS, M.; SANCHEZ, M.; MUXI, A.; FUSTER, D.; SELLARES, J.; MARIETTE, X.; RAMOS-CASALS, M.; BRITO-ZERON, P.
    Objective To characterise the key epidemiological, clinical, immunological, imaging, and pathological features of the coexistence between sarcoidosis and Sjogren's syndrome (SS). Methods All centres included in two large multicentre registries (the Sjogren Syndrome Big Data Consortium and the Sarco-GEAS-SEMI Registry) were contacted searching for potential cases of coexistence between SS and sarcoidosis seen in daily practice. Inclusion criteria were the fulfilment of the current classification criteria both for SS (2016 ACR/EULAR) and sarcoidosis (WASOG). The following features were considered for evaluating a coexisting immunopathological scenario between the two diseases: non-caseating granulomas (NCG), focal lymphocytic sialadenitis (FLS) and positive anti-Ro antibodies. Results We identified 43 patients who fulfilled the inclusion criteria (38 women, with a mean age of 53 years at diagnosis of SS and of 52 years at diagnosis of sarcoidosis). In 28 (65%) cases, sarcoidosis was diagnosed concomitantly with SS, or during the follow-up of patients with an already diagnosed SS, while in the remaining 15 (35%), SS was diagnosed during the follow-up of an already diagnosed sarcoidosis. Patients in whom sarcoidosis was diagnosed first showed a lower mean age (43.88 vs. 55.67 years, p=0.005) and were less frequently women (73% vs. 96%, p=0.04) in comparison with those in whom sarcoidosis was diagnosed concomitantly with SS, or during the follow-up of an already diagnosed SS. We identified the following immunopathological scenarios: a combination of NCG involving extrasalivary tissues and anti-Ro antibodies in 55% of patients, a coexistence of both pathological scenarios (extrasalivary NCG and FLS in MSGB) in 42% (with positive anti-Ro antibodies in two thirds of cases), and NCG involving salivary glands and anti-Ro antibodies in 3% of cases. Conclusion We have characterised the largest reported series of patients who fulfilled the current classification criteria for both SS and sarcoidosis. This implies that sarcoidosis (and not just the presence of isolated NCG on salivary gland biopsy) may, like other systemic autoimmune diseases, coexist with SS, and that a sarcoidosis diagnosis does not preclude the development of SS in the future.
  • article 1 Citação(ões) na Scopus
    Exposure to air pollution as an environmental determinant of how Sjögren's disease is expressed at diagnosis
    (2023) BRITO-ZERON, P.; FLORES-CHAVEZ, A.; NG, W. -F.; HORVATH, I. Fanny; RASMUSSEN, A.; PRIORI, R.; BALDINI, C.; ARMAGAN, B.; OZKIZILTAS, B.; PRAPROTNIK, S.; SUZUKI, Y.; QUARTUCCIO, L.; HERNANDEZ-MOLINA, G.; ABACAR, K.; BARTOLONI, E.; RISCHMUELLER, M.; OLIVEIRA, F. Reis-de; TREVISANI, V. Fernandes Moca; JURCUT, C.; FUGMANN, C.; CARUBBI, F.; HOFAUER, B.; VALIM, V.; PASOTO, S. G.; RETAMOZO, S.; ATZENI, F.; FONSECA-AIZPURU, E.; LOPEZ-DUPLA, M.; GIACOMELLI, R.; NAKAMURA, H.; AKASBI, M.; THOMPSON, K.; SZANTO, A.; FARRIS, A. D.; VILLA, M.; BOMBARDIERI, S.; KILIC, L.; TUFAN, A.; PIRKMAJER, K. Perdan; FUJISAWA, Y.; VITA, S. De; INANC, N.; RAMOS-CASALS, M.
    ObjectiveTo analyse how the potential exposure to air pollutants can influence the key components at the time of diagnosis of Sjogren's phenotype (epidemiological profile, sicca symptoms, and systemic disease). MethodsFor the present study, the following variables were selected for harmonisation and refinement: age, sex, country, fulfilment of 2002/2016 criteria items, dry eyes, dry mouth, and overall ESSDAI score. Air pollution indexes per country were defined according to the OECD (1990-2021), including emission data of nitrogen and sulphur oxides (NO/SO), particulate matter (PM2.5 and 1.0), carbon monoxide (CO) and volatile organic compounds (VOC) calculated per unit of GDP, Kg per 1000 USD.ResultsThe results of the chi-square tests of independence for each air pollutant with the frequency of dry eyes at diagnosis showed that, except for one, all variables exhibited p-values <0.0001. The most pronounced disparities emerged in the dry eye prevalence among individuals inhabiting countries with the highest NO/SO exposure, a surge of 4.61 percentage points compared to other countries, followed by CO (3.59 points), non-methane (3.32 points), PM2.5 (3.30 points), and PM1.0 (1.60 points) exposures. Concerning dry mouth, individuals residing in countries with worse NO/SO exposures exhibited a heightened frequency of dry mouth by 2.05 percentage points (p<0.0001), followed by non-methane exposure (1.21 percentage points increase, p=0.007). Individuals inhabiting countries with the worst NO/SO, CO, and PM2.5 pollution levels had a higher mean global ESSDAI score than those in lower-risk nations (all p-values <0.0001). When systemic disease was stratified according to DAS into low, moderate, and high systemic activity levels, a heightened proportion of individuals manifesting moderate/severe systemic activity was observed in countries with worse exposures to NO/SO, CO, and PM2.5 pollutant levels. ConclusionFor the first time, we suggest that pollution levels could influence how SjD appears at diagnosis in a large international cohort of patients. The most notable relationships were found between symptoms (dryness and general body symptoms) and NO/SO, CO, and PM2.5 levels.
  • article 1 Citação(ões) na Scopus
    Influence of exposure to climate-related hazards in the phenotypic expression of primary Sjögren's syndrome
    (2023) FLORES-CHAVEZ, A.; BRITO-ZERON, P.; NG, W. -f.; SZANTO, A.; RASMUSSEN, A.; PRIORI, R.; BALDINI, C.; ARMAGAN, B.; OEZKIZILTAS, B.; PRAPROTNIK, S.; SUZUKI, Y.; QUARTUCCIO, L.; HERNANDEZ-MOLINA, G.; INANC, N.; BARTOLONI, E.; RISCHMUELLER, M.; OLIVEIRA, F. Reis-de; TREVISANI, V. Fernandes Moca; JURCUT, C.; NORDMARK, G.; CARUBBI, F.; HOFAUER, B.; VALIM, V.; PASOTO, S. G.; RETAMOZO, S.; ATZENI, F.; FONSECA-AIZPURU, E.; LOPEZ-DUPLA, M.; GIACOMELLI, R.; NAKAMURA, H.; AKASBI, M.; THOMPSON, K.; HORVATH, I. Fanny; FARRIS, A. D.; SIMONCELLI, E.; BOMBARDIERI, S.; KILIC, L.; TUFAN, A.; PIRKMAJER, K. Perdan; FUJISAWA, Y.; VITA, S. De; ABACAR, K.; RAMOS-CASALS, M.
    Objective To analyse how the key components at the time of diagnosis of the Sjogren's phenotype (epidemiological profile, sicca symptoms, and systemic disease) can be influenced by the potential exposure to climate-related natural hazards. Methods For the present study, the following variables were selected for harmonisation and refinement: age, sex, country, fulfilment of 2002/2016 criteria items, dry eyes, dry mouth, and overall ESSDAI score. Climate-related hazards per country were defined according to the OECD and included seven climate-related hazard types: extreme temperature, extreme precipitation, drought, wildfire, wind threats, river flooding, and coastal flooding. Climatic variables were defined as dichotomous variables according to whether each country is ranked among the ten countries with the most significant exposure. Results After applying data-cleaning techniques and excluding people from countries not included in the OECD climate rankings, the database study analysed 16,042 patients from 23 countries. The disease was diagnosed between 1 and 3 years earlier in people living in countries included among the top 10 worst exposed to extreme precipitation, wildfire, wind threats, river flooding, and coastal flooding. A lower frequency of dry eyes was observed in people living in countries exposed to wind threats, river flooding, and coastal flooding, with a level of statistical association being classified as strong (p<0.0001 for the three variables). The frequency of dry mouth was significantly lower in people living in countries exposed to river flooding (p<0.0001) and coastal flooding (p<0.0001). People living in countries included in the worse climate scenarios for extreme temperature (p<0.0001) and river flooding (p<0.0001) showed a higher mean ESSDAI score in comparison with people living in no-risk countries. In contrast, those living in countries exposed to worse climate scenarios for wind threats (p<0.0001) and coastal flooding (p<0.0001) showed a lower mean ESSDAI score in comparison with people living in no-risk countries. Conclusion Local exposure to extreme climate-related hazards plays a role in modulating the presentation of Sjogren across countries concerning the age at which the disease is diagnosed, the frequency of dryness, and the degree of systemic activity.